Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + Domvanalimab vs Pembrolizumab in First-Line PD-L1-High Metastatic NSCLC
2022-503071-28-00Phase 3Completed
- Sponsor
- Arcus Biosciences
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Zimberelimab + Domvanalimab with Pembrolizumab (2 arms). Primary endpoint: Overall survival. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-503071-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503071-28-00.